Role of Platelet-Rich Plasma Therapy in the Treatment of Alopecia Areata and Atrophic Acne Scars

In this case report, a 34-year-old woman developed severe alopecia areata after her second COVID-19 vaccination, but her hair fully recovered following six platelet-rich plasma treatments, highlighting PRP as a potential alternative for patients who cannot tolerate or do not respond to corticosteroids.

This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.

This study found that placebo groups in split-scalp PRP trials for androgenetic alopecia showed less hair loss compared to whole-head trial placebo groups, likely due to PRP diffusion in split-scalp designs.

This article reviews the use of platelet-rich plasma (PRP) in various dermatological conditions and reports no new clinical results; the authors emphasize its efficacy and call for continued careful use.

This expert group provided recommendations for preparing and using platelet-rich plasma in treating androgenetic alopecia, suggesting a manual double-spin method and specific dosing, although further studies on injectable platelet-rich fibrin are needed.

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

This review discusses the causes, associated conditions, and treatment options for alopecia areata, such as corticosteroids and wigs, but reports no new clinical findings.